Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results at the virtual ASCO 2020 event May 29-31.
AstraZeneca and Daiichi Sankyo’s Enhertu helped patients with three different types of cancer live longer in trials, pointing to potential broader use of the breast cancer treatment.
Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported.
A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light.
China’s Innovent Biologics forged a licensing agreement with biosimilar-focused Coherus BioSciences to commercialize Innovent’s biosimilar candidate to Avastin (bevacizumab) in the United States and Canada.
The European Commission granted conditional marketing authorization for Libtayo (cemiplimab) for treating adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.
Cancer drug study patients tend to be younger than most people with the disease in the general population.
Bristol-Myers Squibb Company announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.
There was a flurry of activity during the first few days of the American Society of Clinical Oncology, with multiple presentations made showing the benefits of various oncology treatments.